Komori
Governance4888STELLA PHARMA CORPORATIONPharmaceuticals

Matters Concerning Controlling Shareholders

Disclosed that Stella Chemifa Corporation is an other affiliated company holding 33.66% of the voting rights in the Company, along with its procurement transactions with the Company and procedures for protecting minority shareholders. The main text does not state any changes from the previous disclosure.

Worth reading
78Important
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
33.66
Voting rights ownership ratio (%)
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Controlling shareholder
Stella Chemifa Corporation33.66%Voting rights

other affiliated company; voting rights ownership ratio: direct 33.66%, aggregated portion —, total 33.66%

When one company holds most of the voting rights, its wishes are more likely to prevail in management. How the interests of minority shareholders are protected is a key issue.

Committee1
Audit and Supervisory Committee
Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
CommitteeAudit and Supervisory Committee (percentage of outside members: not disclosed)
Controlling shareholderStella Chemifa Corporation (other affiliated company; voting rights ownership ratio: direct 33.66%, aggregated portion —, total 33.66%)
Items this document does not state (5)
Number of directorsNumber of independent officersPolicy on cross-shareholdingsTakeover defensesChanges this time

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To provide information on matters concerning controlling shareholders, etc. The disclosure states that transactions with Stella Chemifa Corporation are necessary because high-purity boron manufactured using the company’s technology is essential for producing the active pharmaceutical ingredient for BNCT boron drugs.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Matters Concerning Controlling Shareholders | STELLA PHARMA CORPORATION (4888) timely disclosure | Komori